489 related articles for article (PubMed ID: 32607960)
41. Quality of Life During and After Completion of Neoadjuvant Chemoradiotherapy for Esophageal and Junctional Cancer.
Noordman BJ; Verdam MGE; Onstenk B; Heisterkamp J; Jansen WJBM; Martijnse IS; Lagarde SM; Wijnhoven BPL; Acosta CMM; van der Gaast A; Sprangers MAG; van Lanschot JJB
Ann Surg Oncol; 2019 Dec; 26(13):4765-4772. PubMed ID: 31620943
[TBL] [Abstract][Full Text] [Related]
42. Preoperative image-guided identification of response to neoadjuvant chemoradiotherapy in esophageal cancer (PRIDE): a multicenter observational study.
Borggreve AS; Mook S; Verheij M; Mul VEM; Bergman JJ; Bartels-Rutten A; Ter Beek LC; Beets-Tan RGH; Bennink RJ; van Berge Henegouwen MI; Brosens LAA; Defize IL; van Dieren JM; Dijkstra H; van Hillegersberg R; Hulshof MC; van Laarhoven HWM; Lam MGEH; van Lier ALHMW; Muijs CT; Nagengast WB; Nederveen AJ; Noordzij W; Plukker JTM; van Rossum PSN; Ruurda JP; van Sandick JW; Weusten BLAM; Voncken FEM; Yakar D; Meijer GJ;
BMC Cancer; 2018 Oct; 18(1):1006. PubMed ID: 30342494
[TBL] [Abstract][Full Text] [Related]
43. Neoadjuvant chemoradiotherapy versus neoadjuvant chemotherapy followed by minimally invasive esophagectomy for locally advanced esophageal squamous cell carcinoma: a prospective multicenter randomized clinical trial.
Tang H; Wang H; Fang Y; Zhu JY; Yin J; Shen YX; Zeng ZC; Jiang DX; Hou YY; Du M; Lian CH; Zhao Q; Jiang HJ; Gong L; Li ZG; Liu J; Xie DY; Li WF; Chen C; Zheng B; Chen KN; Dai L; Liao YD; Li K; Li HC; Zhao NQ; Tan LJ
Ann Oncol; 2023 Feb; 34(2):163-172. PubMed ID: 36400384
[TBL] [Abstract][Full Text] [Related]
44. Neutrophil-to-lymphocyte ratio as a prognostic biomarker for patients with locally advanced esophageal squamous cell carcinoma treated with definitive chemoradiotherapy.
Zhou XL; Li YQ; Zhu WG; Yu CH; Song YQ; Wang WW; He DC; Tao GZ; Tong YS
Sci Rep; 2017 Feb; 7():42581. PubMed ID: 28195186
[TBL] [Abstract][Full Text] [Related]
45. Effects of Neoadjuvant Chemoradiotherapy on Pathological TNM Stage and Their Prognostic Significance for Surgically-treated Esophageal Squamous Cell Carcinoma.
Hamai Y; Hihara J; Emi M; Furukawa T; Ibuki Y; Yamakita I; Kurokawa T; Okada M
Anticancer Res; 2017 Oct; 37(10):5639-5646. PubMed ID: 28982881
[TBL] [Abstract][Full Text] [Related]
46. The predictive value of peripheral blood cells and lymphocyte subsets in oesophageal squamous cell cancer patients with neoadjuvant chemoradiotherapy.
Zhou J; Lin HP; Xu X; Wang XH; Rong L; Zhang Y; Shen L; Xu L; Qin WT; Ye Q; Ma XM; Bai YR
Front Immunol; 2022; 13():1041126. PubMed ID: 36451825
[TBL] [Abstract][Full Text] [Related]
47. Pathologic responses and surgical outcomes after neoadjuvant immunochemotherapy versus neoadjuvant chemoradiotherapy in patients with locally advanced esophageal squamous cell carcinoma.
Xu L; Wei XF; Li CJ; Yang ZY; Yu YK; Li HM; Xie HN; Yang YF; Jing WW; Wang Z; Kang XZ; Zhang RX; Qin JJ; Xue LY; Bi N; Chen XK; Li Y
Front Immunol; 2022; 13():1052542. PubMed ID: 36466925
[TBL] [Abstract][Full Text] [Related]
48. Absolute CT perfusion parameter values after the neoadjuvant chemoradiotherapy of the squamous cell esophageal carcinoma correlate with the histopathologic tumor regression grade.
Djuric-Stefanovic A; Micev M; Stojanovic-Rundic S; Pesko P; Saranovic Dj
Eur J Radiol; 2015 Dec; 84(12):2477-84. PubMed ID: 26467704
[TBL] [Abstract][Full Text] [Related]
49. Association between the thoroughness of the histopathological examination and survival in patients with esophageal squamous cell carcinoma who achieve pathological complete response after chemoradiotherapy.
Chiu CH; Chen WH; Wen YW; Yeh CJ; Chao YK; Chang HK; Tseng CK; Liu YH
Dis Esophagus; 2016 Aug; 29(6):634-41. PubMed ID: 26175202
[TBL] [Abstract][Full Text] [Related]
50. Neutrophil-to-Lymphocyte and Platelet-to-Lymphocyte Ratios can Predict Treatment Response to Neoadjuvant Therapy in Esophageal Cancer.
McLaren PJ; Bronson NW; Hart KD; Vaccaro GM; Gatter KM; Thomas CR; Hunter JG; Dolan JP
J Gastrointest Surg; 2017 Apr; 21(4):607-613. PubMed ID: 28083838
[TBL] [Abstract][Full Text] [Related]
51. Impact of Interval Between Neoadjuvant Chemoradiation and Surgery Upon Morbidity and Survival of Patients with Squamous Cell Carcinoma of Thoracic Esophagus.
Furukawa T; Hamai Y; Hihara J; Emi M; Yamakita I; Ibuki Y; Kurokawa T; Okada M
Anticancer Res; 2018 Sep; 38(9):5239-5245. PubMed ID: 30194173
[TBL] [Abstract][Full Text] [Related]
52. A Pathological Study of Residual Cancer in the Esophageal Wall Following Neoadjuvant Chemoradiotherapy: Focus on Esophageal Squamous Cell Carcinoma Patients with False Negative Preoperative Endoscopic Biopsies.
Chao YK; Tsai CY; Chang HK; Tseng CK; Liu YH; Yeh CJ
Ann Surg Oncol; 2015 Oct; 22(11):3647-52. PubMed ID: 25672562
[TBL] [Abstract][Full Text] [Related]
53. Increasing the interval between neoadjuvant chemoradiotherapy and surgery in esophageal cancer: a meta-analysis of published studies.
Lin G; Han SY; Xu YP; Mao WM
Dis Esophagus; 2016 Nov; 29(8):1107-1114. PubMed ID: 26542065
[TBL] [Abstract][Full Text] [Related]
54. Prognostic Impact of Postoperative Lymph Node Metastases After Neoadjuvant Chemoradiotherapy for Locally Advanced Squamous Cell Carcinoma of Esophagus: From the Results of NEOCRTEC5010, a Randomized Multicenter Study.
Leng X; He W; Yang H; Chen Y; Zhu C; Fang W; Yu Z; Mao W; Xiang J; Chen Z; Yang H; Wang J; Pang Q; Zheng X; Liu H; Yang H; Li T; Zhang X; Li Q; Wang G; Mao T; Guo X; Lin T; Liu M; Fu J; Han Y
Ann Surg; 2021 Dec; 274(6):e1022-e1029. PubMed ID: 31855875
[TBL] [Abstract][Full Text] [Related]
55. Tumor volume regression during neoadjuvant chemoradiotherapy for esophageal cancer: a prospective study with weekly MRI.
Defize IL; Boekhoff MR; Borggreve AS; van Lier ALHMW; Takahashi N; Haj Mohammad N; Ruurda JP; van Hillegersberg R; Mook S; Meijer GJ
Acta Oncol; 2020 Jul; 59(7):753-759. PubMed ID: 32400242
[No Abstract] [Full Text] [Related]
56. [Neoadjuvant chemoradiotherapy combined with surgery versus direct surgery in the treatment of Siewert type II and III adenocarcinomas of the esophagogastric junction: long-term prognostic analysis of a prospective randomized controlled trial].
Tian Y; Wang Q; Wang J; Qiao XY; Zhang J; Lin YC; Li Y; Fan LQ; Yang PG; Zhao Q
Zhonghua Wei Chang Wai Ke Za Zhi; 2021 Feb; 24(2):128-137. PubMed ID: 33508918
[No Abstract] [Full Text] [Related]
57. Correlation between the pretherapeutic neutrophil to lymphocyte ratio and the pathologic response to neoadjuvant chemotherapy in patients with advanced esophageal cancer.
Sato H; Tsubosa Y; Kawano T
World J Surg; 2012 Mar; 36(3):617-22. PubMed ID: 22223293
[TBL] [Abstract][Full Text] [Related]
58. Predicting Response to Neoadjuvant Chemoradiotherapy in Esophageal Cancer with Textural Features Derived from Pretreatment
Beukinga RJ; Hulshoff JB; van Dijk LV; Muijs CT; Burgerhof JGM; Kats-Ugurlu G; Slart RHJA; Slump CH; Mul VEM; Plukker JTM
J Nucl Med; 2017 May; 58(5):723-729. PubMed ID: 27738011
[TBL] [Abstract][Full Text] [Related]
59. Comparison of neoadjuvant chemotherapy or chemoradiotherapy plus immunotherapy for locally resectable esophageal squamous cell carcinoma.
Yang G; Yue H; Zhang X; Zeng C; Tan L; Zhang X
Front Immunol; 2024; 15():1336798. PubMed ID: 38779667
[TBL] [Abstract][Full Text] [Related]
60. Good prediction of treatment responses to neoadjuvant chemoradiotherapy for esophageal cancer based on preoperative inflammatory status and tumor glucose metabolism.
Li C; Lin JW; Yeh HL; Chuang CY; Chen CC
Sci Rep; 2021 Jun; 11(1):11626. PubMed ID: 34078965
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
